Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients

Background:Treatment of Medication Overuse Headache (MOH) is yet under debate and Celecoxib as a Cyclooxygenase 2 (COX2) -inhibitor has not been tried widely as a pain relief drug for this type of headaches in migrainous patients.  Objectives: comparing the efficacy of celecoxib versus prednisolone...

Full description

Bibliographic Details
Main Authors: Ahmad Chitsaz, Mohammadreza Najafi, Maryam Shirmardi, Roshanak Mehdipour
Format: Article
Language:English
Published: Guilan University of Medical Sciences 2018-01-01
Series:Caspian Journal of Neurological Sciences
Subjects:
Online Access:http://cjns.gums.ac.ir/browse.php?a_code=A-10-131-4&slc_lang=en&sid=1
id doaj-8c711273656142e99a454f135df9268a
record_format Article
spelling doaj-8c711273656142e99a454f135df9268a2020-11-24T21:56:36ZengGuilan University of Medical SciencesCaspian Journal of Neurological Sciences2383-43072423-48182018-01-014121317Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous PatientsAhmad Chitsaz0Mohammadreza Najafi1Maryam Shirmardi2Roshanak Mehdipour3 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Background:Treatment of Medication Overuse Headache (MOH) is yet under debate and Celecoxib as a Cyclooxygenase 2 (COX2) -inhibitor has not been tried widely as a pain relief drug for this type of headaches in migrainous patients.  Objectives: comparing the efficacy of celecoxib versus prednisolone for withdrawal period of MOH. Materials & Methods: A double-blind, randomized clinical trial was carried out, on 75 patients with MOH who visited the Isfahan Neurology Clinic in 2016. They were assigned into two groups of oral prednisolone and celecoxib prescribed for 15 days. Any changes in the duration (average hours of daily headache), frequency, and severity of headaches, and intake of rescue medication and their side effects were recorded after the 15-day intervention period. Data were analyzed by independent t, paired t, Mann-Whitney, Wilcoxon test, and chi-square tests in SPSS software version 20. Results: Average duration of headache in both groups significantly decreased after treatment (P<0.001). It decreased significantly in celecoxib group (P=0.04). Headache frequency decreased more but not significantly in the celecoxib group (P=0.08). Considering MIGSEV (Migraine Severity) and VAS (Visual Analogue Scale) scales, headache severity alleviated significantly after treatment in both groups (P<0.001). The decrease was more noticeable in the celecoxib group. Need for rescue medications (P=0.048), and side effect appearance (P=0.001) was also lower in patients who took celecoxib, compared to the other group. Conclusion: Celecoxib showed higher efficacy and fewer side effects, compared to prednisolone in treatment of medication overuse headache in migrainous patients.http://cjns.gums.ac.ir/browse.php?a_code=A-10-131-4&slc_lang=en&sid=1HeadacheCelecoxibPrednisolone
collection DOAJ
language English
format Article
sources DOAJ
author Ahmad Chitsaz
Mohammadreza Najafi
Maryam Shirmardi
Roshanak Mehdipour
spellingShingle Ahmad Chitsaz
Mohammadreza Najafi
Maryam Shirmardi
Roshanak Mehdipour
Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
Caspian Journal of Neurological Sciences
Headache
Celecoxib
Prednisolone
author_facet Ahmad Chitsaz
Mohammadreza Najafi
Maryam Shirmardi
Roshanak Mehdipour
author_sort Ahmad Chitsaz
title Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
title_short Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
title_full Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
title_fullStr Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
title_full_unstemmed Celecoxib or Prednisolone for Treatment of Medication Overuse Headache: A Randomized, Double-Blind Clinical Trial in Migrainous Patients
title_sort celecoxib or prednisolone for treatment of medication overuse headache: a randomized, double-blind clinical trial in migrainous patients
publisher Guilan University of Medical Sciences
series Caspian Journal of Neurological Sciences
issn 2383-4307
2423-4818
publishDate 2018-01-01
description Background:Treatment of Medication Overuse Headache (MOH) is yet under debate and Celecoxib as a Cyclooxygenase 2 (COX2) -inhibitor has not been tried widely as a pain relief drug for this type of headaches in migrainous patients.  Objectives: comparing the efficacy of celecoxib versus prednisolone for withdrawal period of MOH. Materials & Methods: A double-blind, randomized clinical trial was carried out, on 75 patients with MOH who visited the Isfahan Neurology Clinic in 2016. They were assigned into two groups of oral prednisolone and celecoxib prescribed for 15 days. Any changes in the duration (average hours of daily headache), frequency, and severity of headaches, and intake of rescue medication and their side effects were recorded after the 15-day intervention period. Data were analyzed by independent t, paired t, Mann-Whitney, Wilcoxon test, and chi-square tests in SPSS software version 20. Results: Average duration of headache in both groups significantly decreased after treatment (P<0.001). It decreased significantly in celecoxib group (P=0.04). Headache frequency decreased more but not significantly in the celecoxib group (P=0.08). Considering MIGSEV (Migraine Severity) and VAS (Visual Analogue Scale) scales, headache severity alleviated significantly after treatment in both groups (P<0.001). The decrease was more noticeable in the celecoxib group. Need for rescue medications (P=0.048), and side effect appearance (P=0.001) was also lower in patients who took celecoxib, compared to the other group. Conclusion: Celecoxib showed higher efficacy and fewer side effects, compared to prednisolone in treatment of medication overuse headache in migrainous patients.
topic Headache
Celecoxib
Prednisolone
url http://cjns.gums.ac.ir/browse.php?a_code=A-10-131-4&slc_lang=en&sid=1
work_keys_str_mv AT ahmadchitsaz celecoxiborprednisolonefortreatmentofmedicationoveruseheadachearandomizeddoubleblindclinicaltrialinmigrainouspatients
AT mohammadrezanajafi celecoxiborprednisolonefortreatmentofmedicationoveruseheadachearandomizeddoubleblindclinicaltrialinmigrainouspatients
AT maryamshirmardi celecoxiborprednisolonefortreatmentofmedicationoveruseheadachearandomizeddoubleblindclinicaltrialinmigrainouspatients
AT roshanakmehdipour celecoxiborprednisolonefortreatmentofmedicationoveruseheadachearandomizeddoubleblindclinicaltrialinmigrainouspatients
_version_ 1725858197791571968